Source comparison
Tesamorelin for Visceral Fat Research: Comparison
Tesamorelin 2mg daily GHRH analogue. Restores pulsatile GH secretion 15–18% (NEJM trials) Minimal (<2%) IGF-1 ↑, glucose tolerance unchanged, triglycerides ↓ 15–20% Most selective VAT reduction of any pharmacological intervention. Requires continued use to mai
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- GHRH analogue. Restores pulsatile GH secretion
- 15–18% (NEJM trials)
- Minimal (<2%)
- IGF-1 ↑, glucose tolerance unchanged, triglycerides ↓ 15–20%
- Most selective VAT reduction of any pharmacological intervention. Requires continued use to maintain effect
- Dietary caloric restriction
- Energy deficit. Triggers lipolysis systemically
- 3–5% in HIV lipodystrophy cohorts
- Proportional to total fat loss
- Metabolic adaptation, leptin ↓, ghrelin ↑, NEAT ↓ 200–400 kcal/day
- Non-selective. Loses subcutaneous and visceral fat equally, difficult to sustain long-term due to hormonal adaptation
- Exogenous GH (0.3–1.0mg/day)
- Direct GH replacement. Suppresses endogenous pulsatility
- 10–15% (smaller trials)
- Variable (0–5%)
- Hyperglycemia risk, edema, arthralgias common
- Greater side effect burden than tesamorelin, suppresses natural GH production, higher cost
- GLP-1 receptor agonists (semaglutide 2.4mg weekly)
- Appetite suppression + delayed gastric emptying
- 8–12% (inferred from total fat loss data)
- A1C ↓ 1.5–2%, systolic BP ↓ 3–5 mmHg
- Non-selective for VAT, works through caloric deficit mechanism, strong glucose-lowering effect useful in diabetic populations